Published in Gastroenterology on February 15, 2011
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci (2011) 1.50
Inhibition of hepcidin transcription by growth factors. Hepatology (2012) 1.17
An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. Dis Model Mech (2011) 1.17
Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging (2014) 0.94
Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients (2013) 0.92
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Hepcidin and Host Defense against Infectious Diseases. PLoS Pathog (2015) 0.89
Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk. Dis Markers (2015) 0.84
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Inverse Association of Plasma Level of Glutathione Peroxidase with Liver Fibrosis in Chronic Hepatitis B: Potential Role of Iron. Middle East J Dig Dis (2016) 0.75
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol (2011) 0.75
Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. Transfusion (2014) 0.75
A Single Center Study Comparing the Stainable Iron Depositions in 1000 Explanted Cirrhotic Livers of Different Causes. Hepat Mon (2015) 0.75
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet (1996) 26.06
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet (2002) 7.90
Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet (2008) 4.02
Regulation of iron metabolism by hepcidin. Annu Rev Nutr (2006) 3.96
The serine protease TMPRSS6 is required to sense iron deficiency. Science (2008) 3.70
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood (2008) 2.75
Iron and chronic viral hepatitis. Hepatology (1997) 2.18
Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol (2007) 1.85
Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med (2000) 1.84
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology (2008) 1.81
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol (1995) 1.68
Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med (2007) 1.59
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab (2008) 1.33
Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut (1997) 1.26
Iron in nonhemochromatotic liver disorders. Semin Liver Dis (2005) 1.25
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology (1992) 1.16
Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol (2003) 1.12
Iron in liver diseases other than hemochromatosis. Semin Liver Dis (1996) 1.12
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol (2002) 0.99
Iron-induced liver injury. Clin Liver Dis (2000) 0.98
HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol (2003) 0.97
Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology (2005) 0.92
Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci (2007) 0.88
Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol (1992) 0.83
Spectrophotometric determination of iron in heme proteins. Methods Enzymol (1986) 0.77
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med (2010) 7.95
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA (2006) 7.60
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health. Soc Sci Med (2005) 6.14
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin (2012) 3.58
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Cancer statistics for African Americans, 2013. CA Cancer J Clin (2013) 2.44
Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. J Urol (2008) 2.43
A comprehensive worksite cancer prevention intervention: behavior change results from a randomized controlled trial (United States). Cancer Causes Control (2002) 2.42
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog (2010) 2.33
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem (2005) 2.05
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med (2012) 1.92
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology (2007) 1.85
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83